Onkologie. 2013:7(1):10-12

Anticancer activity of bisphosphonates

Katarína Petráková

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Bisphosphonates are commonly used in patients with breast cancer to reduce skeletal-related events in metastatic disease and to

mitigate bone loss associated with adjuvant therapy. Preclinical studies have shown that bisphosphonates may directly inhibit breast

cancer cell proliferation and metastasis. Subsequently, trials of zoledronic acid have demonstrated prolonged disease-free survival in

postmenopausal or otherwise estrogen-depleted women with early breast cancer. In the ABCSG-12 trial, the addition of twice-yearly

zoledronic acid (4 mg IV) to adjuvant endocrine therapy improved disease-free survival in premenopausal women undergoing ovarian

suppression. Similar results were observed in postmenopausal women receiving aromatase inhibitors in the ZO-FAST trial, and in women

who were at least 5 years past menopause in the AZURE trial.

Keywords: bisphosphonates, anricancer effect, adjuvant zoledronat

Published: February 1, 2013  Show citation